Chlamydia pneumoniae — a common bacterium that causes pneumonia and sinus infections — was found at significantly higher levels in the retinas and brains of Alzheimer's patients compared to cognitively healthy controls. Published in Nature Communications in February 2026, the Cedars-Sinai study analyzed retinal tissue from 104 people and found that the bacterium activates the NLRP3 inflammasome, triggering inflammation, nerve cell death, and amyloid-beta accumulation. The association was strongest in carriers of the APOE4 gene — the highest-risk genetic variant for Alzheimer's.
The retina is embryologically part of the brain — it extends outward during development but retains direct neural connections. What lives in the retina lives in the brain. The researchers propose the retina as a noninvasive window for monitoring Alzheimer's pathology: bacterial load in the eye predicts disease status in the brain.
The structural insight is about chronic infection as infrastructure for neurodegeneration. Alzheimer's research has focused on two hypotheses: amyloid cascade (protein buildup causes disease) and tau phosphorylation (cytoskeletal collapse causes disease). The Chlamydia result suggests a third possibility: chronic low-grade infection creates the inflammatory environment in which both amyloid and tau pathology accelerate. The infection doesn't cause Alzheimer's. It creates the conditions under which the brain's normal clearance mechanisms fail.
This changes the therapeutic logic. If infection-driven inflammation is a contributing factor, then antibiotics or anti-inflammatory treatments administered early — before amyloid accumulation reaches clinical thresholds — might slow progression. The intervention point moves backward in time, from treating symptoms to preventing the inflammatory substrate that enables them. And the monitoring tool is the eye, not the brain — accessible, non-invasive, and repeatable.